Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 6/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 2/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | PAK4 | O96013 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31227179 | 0.77 | KMT2A (0.51) | HRH3CYP2A6NPC1RAB9AKDM4E | |
| SCHEMBL2760450 | 0.77 | KMT2A (0.51) | HRH3CYP2A6NPC1RAB9AKDM4E | |
| SCHEMBL30336854 | 0.77 | CYP2A6 (0.42) | HRH3CYP2A6LTA4HNPC1RAB9A | |
| SCHEMBL1977093 | 0.77 | PIK3CD (0.56) | CYP2A6NPC1RAB9AKDM4EPIK3CD | |
| SCHEMBL1761538 | 0.77 | HRH3 (0.40) | HRH3CYP2A6LTA4HNPC1RAB9A | |
| SCHEMBL1891413 | 0.77 | CYP2A6 (0.42) | HRH3CYP2A6LTA4HNPC1RAB9A | |
| SCHEMBL15164320 | 0.76 | RAB9A (0.51) | NPC1RAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL31109877 | 0.75 | PIK3CD (0.54) | CYP2A6NPC1RAB9AKDM4EPIK3CD | |
| SCHEMBL23458507 | 0.74 | RAB9A (0.68) | NPC1RAB9AKDM4EPIK3CDPIK3CA | |
| SCHEMBL26538335 | 0.74 | CYP2C9 (0.46) | CYP2A6KDM4EMYCCHEK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118878514-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2024-11-01 | — | — | CN | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-115427394-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | HRH3 220/4885CYP2A6 337/4885LTA4H 289/4885 |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | HRH3 282/4885CYP2A6 214/4885LTA4H 251/4885 |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | HRH3 3772/4885CYP2A6 1719/4885LTA4H 4260/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | HRH3 220/4885CYP2A6 337/4885LTA4H 289/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | HRH3 3772/4885CYP2A6 1719/4885LTA4H 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.